Efficasy and safety of intrathecal injection of autologous mesenchymal stem cells in patients with amyotrophic lateral sclerosis (ALS)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200828048551N1

Enrollment

Registered

2020-09-09

Start date

2020-02-24

Completion date

Unknown

Last updated

2020-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis

Interventions

Intrathecal injection of mesenchymal stem cells.

Eligibility

Sex/Gender

All

Age

25 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients diagnosed as definite or probable ALS disease according to EL Escorial criteria ALSFRS-R more than 26 FVC more than 40% age 25-70 years Time passed since onset of the symptoms till inclusion be 3 years or less

Exclusion criteria

Exclusion criteria: Any major systemic disease Any coexisting neurodegenerative disease No other major pathology in brain or spinal cord pregnancy or lactation

Design outcomes

Primary

Measure	Time frame
Disability. Timepoint: 3 months. Method of measurement: ALSFRS-R.;Forced vital capacity. Timepoint: 3 months. Method of measurement: spirometry.;Side effects. Timepoint: 3 months. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Gholamreza Shamsaei

Ahvaz University of Medical Sciences

Shamsaei-gh@ajums.ac.ir+98 61 3374 3001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 13, 2026